Evaluation of treatment response with PERCIST in follicular lymphoma receiving rituximab single-agent immunotherapy

被引：0

作者：

Tatsumi, Mitsuaki ^{[1
]}

Watabe, Tadashi ^{[1
]}

Kato, Hiroki ^{[1
]}

Imaizumi, Masao ^{[1
]}

Shimosegawa, Eku ^{[1
]}

Hatazawa, Jun ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan

来源：

JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

1364

引用

页数：2

共 50 条

[31] Intermittent Single-Agent Doxorubicin for the Treatment of Canine B-Cell Lymphoma
Higginbotham, Mary Lynn
McCaw, Dudley L.
Roush, James K.
Nietfeld, Jerome C.
Wilkerson, Melinda J.
Reeds, Kimberly
Burr, Diana
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 2013, 49 (06) : 357 - 362
[32] Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
Stenner, Frank
Renner, Christoph
FRONTIERS IN ONCOLOGY, 2018, 8
[33] Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab
Hirt, C
Schüler, F
Dölken, G
SEMINARS IN CANCER BIOLOGY, 2003, 13 (03) : 223 - 231
[34] Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
Hilchey, Shannon P.
Hyrien, Ollivier
Mosmann, Tim R.
Livingstone, Alexandra M.
Friedberg, Jonathan W.
Young, Faith
Fisher, Richard I.
Kelleher, Raymond J., Jr.
Bankert, Richard B.
Bernstein, Steven H.
BLOOD, 2009, 113 (16) : 3809 - 3812
[35] Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study
Barraclough, Allison
Chong, Geoff
Gilbertson, Michael
Grigg, Andrew
Churilov, Leonid
Fancourt, Tineke
Ritchie, David
Koldej, Rachel
Agarwal, Rishu
Manos, Kate
Smith, Charmaine
Houdyk, Kristen
Hawking, Joanne
Hawkes, Eliza
BLOOD, 2019, 134
[36] Failure of single-agent rituximab for treatment of subcutaneous intravascular lymphomatosis (IVL): A case report.
Pirog, Steven C.
Aboulafia, David M.
BLOOD, 2006, 108 (11) : 255B - 256B
[37] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Michael Wang
Simon Rule
Pier Luigi Zinzani
Andre Goy
Olivier Casasnovas
Stephen D. Smith
Gandhi Damaj
Jeanette K. Doorduijn
Thierry Lamy
Franck Morschhauser
Carlos Panizo
Bijal Shah
Andrew Davies
Richard Eek
Jehan Dupuis
Eric Jacobsen
Arnon P. Kater
Steven Le Gouill
Lucie Oberic
Tadeusz Robak
Preetesh Jain
Melanie M. Frigault
Raquel Izumi
Dorothy Nguyen
Priti Patel
Ming Yin
Monika Długosz-Danecka
Leukemia, 2019, 33 : 2762 - 2766
[38] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Olivier
Smith, Stephen D.
Damaj, Gandhi
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Tadeusz
Jain, Preetesh
Frigault, Melanie M.
Izumi, Raquel
Dorothy Nguyen
Patel, Priti
Yin, Ming
Dlugosz-Danecka, Monika
LEUKEMIA, 2019, 33 (11) : 2762 - 2766
[39] Predictors of Early Response to Single Agent Rituximab in Patients with Indolent Lymphoma.
Cornec, Divi
Tempescul, Adrian
Querellou, Solene
Mankai, Amani
Hutin, Pascal
Cymbalista, Florence
Berthou, Christian
Renaudineau, Yves
Youinou, Pierre
BLOOD, 2009, 114 (22) : 771 - 771
[40] Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia
Wiernik, Peter H.
Adiga, Giridhar U.
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (10) : 1987 - 1993

← 1 2 3 4 5 →